Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD1a and langerin: acting as more than Langerhans cell markers
Norikatsu Mizumoto, Akira Takashima
Norikatsu Mizumoto, Akira Takashima
View: Text | PDF
Commentary

CD1a and langerin: acting as more than Langerhans cell markers

  • Text
  • PDF
Abstract

Langerhans cells (LCs) represent a unique DC subset populating the outermost body surface, i.e., the epidermis. Although CD1a and langerin (CD207) are used as specific markers to distinguish LCs from other DC subsets, their immunological functions have remained mostly unknown. A new paper (see the related article beginning on page 701) demonstrates that LCs utilize these markers to induce cellular immune responses to Mycobacterium leprae: CD1a mediates the presentation of nonpeptide antigens to T cells, while langerin facilitates uptake of microbial fragments and perhaps their delivery to a specialized subcellular compartment.

Authors

Norikatsu Mizumoto, Akira Takashima

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Geographic and functional coupling of CD1 isoforms and C-type lectins. (...
Geographic and functional coupling of CD1 isoforms and C-type lectins. (A) CD1a molecules are transported from the cell surface to early recycling vesicles and Birbeck granules. Glycolipid antigens captured by langerin are also internalized selectively to Birbeck granules, where CD1a is coupled with lipid moieties. This pathway enables LCs to present lipid antigens to CD1a-restricted T cells. (B) CD1b molecules recycle to early endosomes and then late endosomes, and MMR and DC-SIGN deliver glycolipid antigens to these subcompartments, respectively. Certain DC subsets (e.g., dermal DCs) may employ these pathways for CD1b-restricted lipid antigen presentation. (C) Glycoprotein antigens can be internalized via DEC-205 to MIICs, where peptide antigens bind to MHC class II molecules. This pathway presumably promotes MHC II–restricted peptide antigen presentation by many DC subsets known to express DEC-205.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts